DiaMedica Therapeutics closes $30.1 million private placement

MINNEAPOLIS - DiaMedica Therapeutics Inc. (NASDAQ:DMAC), whose stock has gained over 15% in the past week according to InvestingPro data, announced Wednesday the completion of a $30.1 million private placement, selling approximately 8.6 million common shares at $3.50 per share to accredited investors.

The clinical-stage biopharmaceutical company, which develops treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, received net proceeds of approximately $29.9 million after deducting estimated offering expenses.

As of March 31, 2025, DiaMedica reported cash, cash equivalents and short-term investments of $37.3 million. With the addition of the private placement proceeds, the company’s pro forma cash position would have been $67.2 million.

Several related parties participated in the financing, including Thomas von Koch through TomEnterprise Private AB, which acquired 2,857,142 shares for $10 million, increasing von Koch’s ownership to approximately 16.2% of outstanding shares. Trill AB purchased 1,542,857 shares for $5 million, raising its stake to about 13.1%, while Richard Jacinto II acquired 400,000 shares for $1.4 million.

The securities sold have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption. DiaMedica has agreed to file a registration statement with the SEC within ten days of closing to register the resale of these shares.

DiaMedica’s lead candidate, DM199, is a recombinant form of human tissue kallikrein-1 (KLK1), a protein that regulates various physiological processes. The FDA granted Fast Track Designation to DM199 for acute ischemic stroke treatment in September 2021.

This article is based on information from a company press release.

In other recent news, DiaMedica Therapeutics Inc. has secured $30.1 million through a private placement to support its clinical development programs targeting preeclampsia, fetal growth restriction, and acute ischemic stroke. The company plans to issue 8,606,426 common shares at $3.50 each to existing investors, with the transaction expected to close by late July 2025. Additionally, DiaMedica announced positive interim results from its Phase 2 study of DM199 for preeclampsia, showing significant reductions in blood pressure and improved uterine blood flow. Following these promising results, H.C. Wainwright raised its price target for DiaMedica to $12 from $10, maintaining a Buy rating on the stock. The firm had previously reaffirmed its $10 price target and Buy rating after a key opinion leader event highlighted DM199’s potential as a treatment for preeclampsia. DiaMedica also reported the outcomes of its 2025 Annual General Meeting, where seven board members were re-elected, and an independent registered public accounting firm was appointed. The meeting achieved a 45.1% quorum of voting common shares, with the re-elected directors set to serve until the next annual meeting.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.